Skip to Content

MD Anderson Events

Updates in Cancer Immunotherapy and Toxicity Management

Updates in Cancer Immunotherapy and Toxicity Management

This is a 2-Day Seminar.  Breakfast is served at 7:30 a.m.  Lecture starts at 8:00 a.m. and ends at 4:00 p.m. Each day has morning and afternoon sessions.  Each session ends with discussion panel.

Seminar Goal:

There has been a paradigm shift in the management of patients with advanced cancer from “one size fits all” to providing personalized therapy tailored to the molecular landscape of the tumor. However, in recent years, breakthrough discoveries of immune checkpoints and durable responses observed with immunotherapeutic agents has been more transformative and has led to regulatory approval of the several checkpoint inhibitors for specific indications. 

Prompted by the success of these checkpoint inhibitors, increasing number of immunotherapeutic agents are being investigated across the tumor board, which presents unique challenges to the treating physician. As immunotherapy works by unleashing the suppressed immune system to attack tumor cells rather than attacking the tumor cells directly, immunotherapeutic agents differ significantly from chemotherapeutic agents and consequently pose monitoring and managing toxicity challenges for medical teams, community oncologists, emergency room physicians, etc. 
 
Furthermore, with success being made with these drugs, more and more cancer patients are demanding these drugs as first line therapies for the management of their cancers.
This seminar seek to provide an avenue to bring updates on the application of immunotherapy in treatment of various cancers and the management of their accompanying toxicities to community providers who are interested in winning the fight against cancer.
 
This seminar seek to provide an avenue to bring updates on the application of immunotherapy in treatment of various cancers and the management of their accompanying toxicities to community providers who are interested in winning the fight against cancer
 
Educational Objectives
 
After attending the activity, participants should be able to

·         Demonstrate an understating of developmental therapeutics, the pathophysiology and application of the immunotherapy drugs (knowledge, competence, performance)

·         Become competent in use of biomarkers and monitoring of response to immunotherapy drugs (knowledge, competence)

·         Identify and avoid contraindications to immunotherapy drugs (knowledge, competence, performance, patient outcomes)

·         Assess the application of immunotherapy drugs in cancer management including in combination with cytotoxic drugs, targeted therapy and radiation therapy (knowledge, competence)

·         Recognize and manage toxicities associated with the drugs early to avoid disastrous outcomes for patients (knowledge, competence, performance, patient outcomes)

        
        
 
Target Audience:
    • Physicians
    • Fellows/Students
    • Physician Assistants
    • Pharmacists
    • Research Coordinators/Researchers
    • Registered Nurses
Speakers comprise of experts faculties in field of Immunotherapy and cancer management from MD Anderson Cancer Center and Baylor College of Medicine.
  
Faculty List:

 
Anne K. Brinkman, APRN 
Advanced Prac Registered Nurse
Endocrine Neoplasia & HD               
MD Anderson Cancer Center
 
Ahmed Elsayem, MD
Professor                    
Emergency Medicine 
MD Anderson Cancer Center
 
Loretta J. Nastoupil, MD
Assistant Professor
Lymphoma/Myeloma
MD Anderson Cancer Center
 
Jianjun Gao, MD
Associate Professor
Urology
MD Anderson Cancer Center
 
Isabella C Glitza Oliva, MD, PhD
Assistant Professor                
Melanoma Medical Oncology           
MD Anderson Cancer Center
 
Joud Hajjar, MD     
Assistant Professor    
Immunology, Allergy & Rheumatology
Baylor College of Medicine and Texas Children's Hospital
 
Eucharia Iwuanyanwu, DHSc, PA-C
Physician Assistant                            
Investigational Cancer Therapeutics
MD Anderson Cancer Center
 
Sang Taek Kim, MD, PhD
Instructor
General Internal Medicine
MD Anderson Cancer Center
 
Altan Mehmet, MD
Assistant Professor
Thoracic/Head & Neck Medical Oncology   
MD Anderson Cancer Center
 
 
Agenda: 
 
Day 1 - March 23, 2018  
 
7:30-8:00 a.m.          Breakfast
 
8:00-8:10 a.m.          Program and First Speaker Introduction        
 
8:10-8:50 a.m.           Immune system review and cancer escape mechanism.      Joud Hajjar, MD
 
8:50-9:40 a.m.            Immunotherapy and management of Head &
Neck cancers: Updates.               Altan Mehmet, MD
 
9:40-10:20 a.m.          Advances in immunotherapy: Sarcomas
                                                Neeta Somaiah, MD
 
10:20-11:00                 Advances in immunotherapy& Melanoma                     Management.                       Isabella C Glitza Oliva, MD, PhD
 
11:00-11:10 a.m.                    Break
 
11:10-11:35 a.m.         Biomarkers and correlates of clinical response in cancer immunotherapy.     Aung Naing, MD
 
11:35-12:00 p.m.          Panel Discussion
                         
12:00- 12:50 p.m.         Lunch
 
12:50-1:30: p.m.            Immune based therapies in gastrointestinal cancers (Colon & Pancreatic). Shubham Pant, MBBS
 
1:30-2:10 p.m.               Lymphoma and Immunotherapy: Better Outcomes
                                            Loretta J. Nastoupil, MD
 
2:10-2:55 p.m.               Advances in immunotherapy in Bladder and Renal Cancers.                           Jianjun Gao, MD
 
2:55-3:35 p.m.              Endocrine Toxicities
                                              Anne K. Brinkman, APRN
 
3:35-4:00 p.m.              Panel Discussion  
 
 

Day 2- March 23, 2018          

7:30-8:00 a.m.              Breakfast
 
8:00-8:10 a.m.               Introduction of Program and First Speaker
        
8:10-9:00 a.m.                Dermatological toxicity: What to expect & management.       Anish Patel, MD
 
9:00-9:50 a.m.                  Recognizing and managing gastrointestinal toxicities (ileitis
                                                Colitis, hepatitis, pancreatitis)
                                                Ethan Miller, MD
 
9:50-10:00 a.m.                 Break
 
9:50-10:50 a.m.                  Immunotherapy and Lung Cancer management: Updates. George Simon, MD
 
10:50-11:30 a.m.                Immunotherapy pulmonary toxicity and management.              Vicki Shannon, MD
 
11:30-12:00 p.m.                Panel Discussion
 
12:00-12:50 p.m.                Lunch
 
12:50-1:30 p.m.                   Autoimmune diseases: Contraindications to immunotherapy.
                                                Sang Taek Kim, MD, PhD
 
1:30-2:00 p.m.                      Education for the patient on immunotherapy       Eucharia Iwuanyanwu, DHSc, PA-C
 
2:00-2:45 p.m.                      Neurotoxicity of Immunotherapy and Management.            Sudhaka Tummala, MD
                                      
2:45-3:30 p.m.                       Immunotherapy adverse event:
                                                A visit with the emergency room physician
                                                Ahmed Elsayem, MD
                                      
3:30:4:00 p.m.                        Panel Discussion
 
Ethan Miller, MD
Assistant Professor
GI Herpetology & Nutrition  
MD Anderson Cancer Center
 
Aung Naing, MD
Professor        
Investigational Cancer Therapeutics
MD Anderson Cancer Center
 
Shubham Pant, MBBS
Associate Professor                                        
Investigational Cancer Therapeutics  
MD Anderson Cancer Center
 
Anish Patel, MD
Assistant Professor
Dermatology  
MD Anderson Cancer Center
 
Vicki Shannon, MD
Professor                    
Pulmonary Medicine  
MD Anderson Cancer Center
 
George Simon, MD
Professor
Thoracic/Head & Neck Medical Oncology
MD Anderson Cancer Center
 
Neeta Somaiah, MD
Assistant Professor
Sarcoma Medical Oncology              
MD Anderson Cancer Center
                                   
Sudhaka Tummala, MD
Professor                    
Neurology
MD Anderson Cancer Center
 

 For Registration: Go To http://acecancercareinc.org/

Date: 3/23/18 to 3/24/18
Time: 3/23/18, 7:30am to 3/24/18, 4pm
Location: Double Tree by Hilton Hotel, 8181 Airport Blvd., Houston, TX 77061
Directions: Coming from 45 N, exit Airport Blvd and turn right. If coming from 45 S, exit and turn left. If coming from I-59 or 610, follow I-45 , exit Airport Blvd and turn right.
Format: Seminar/Conference
CME: This live activity has been approved for AMA PRA Category 1 Credits™. Physician Assistants and Pharmacists (in Texas) can claim AMA PRA Category 1 Credits™. Request for Nurses contact hours submitted to TNA.
Facilitator: Eucharia Iwuanyanwu
Speaker: Key Note Speaker: Dr. Aung Naing
Speaker Bio: Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and the PI of this study. Our department currently has 125 phase I trials with an emphasis on novel, targeted agents, especially immunotherapy-based regimens. He has extensive experience conducting innovative clinical trials to determine dose levels, safety profiles, and preliminary efficacy. Dr. Naing serves as the Principal Investigator on 24 of these trials. Focusing on clinical translation of basic immunobiology, his research is aimed at (1) identifying immunologic biomarkers or proteins to predict responders versus non-responders on immunotherapy-based clinical trials, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies. He serve on MD Anderson’s Institutional Research Grant Review Committee as a member of the Study Section Review Committee for Clinical Translational and Population Based Research projects and on the Institutional Review Board (IRB). He is also a member of the MS/PhD Steering Committee, Clinical Research Advisory Committee, and Cancer Network Protocol Review, Integration & Strategic Management (PRISM). In addition, and American Society of Clinical Oncology’s (ASCO) Developmental Therapeutics - Clinical Pharmacology and Immunotherapy Committee. As a member of the Early Therapeutics Committee of the SWOG. Currently, he serves as the course director for Tumor Immunology at The University of Texas Graduate School of Biomedical Sciences at Houston. He is part of The MD Anderson Immunotherapy and Rare Tumor Working Group.
Sponsor: Ace Cancer Care Inc & MD Anderson Cancer Center
Contact: Eucharia Iwuanyanwu - (713) 792-9882 - eiwuany@mdanderson.org